A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ibrutinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 09 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 12 Dec 2017 Interim results (n=16) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology